Jet Injection for Influenza (JIFI)
Jet Injection for Influenza: A Randomized Controlled Clinical Trial to Demonstrate Non Inferiority of Jet Injection vs. Needle and Syringe for Administration of Trivalent Inactivated Influenza Vaccine
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Colorado
-
Fort Collins, Colorado, Stany Zjednoczone, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Stany Zjednoczone, 80528
- University of Colorado Health Harmony Campus
-
Loveland, Colorado, Stany Zjednoczone, 80538
- Medical Center of the Rockies
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Adults aged ≥18 and ≤64 years of age at the time of enrollment
- Willing and able to give informed consent after reading the consent form and adequate opportunity to discuss the study with the investigator or qualified designee
- Willing and able to adhere to all protocol required study procedures and to attend scheduled visits.
- Able to receive the TIV influenza vaccine, based on University of Colorado Health (UCH) employee health flu screening guidelines.
- Stable health status with no exclusionary medical or neuropsychiatric conditions as determined during the screening evaluation and based on the clinical judgment of the investigator or qualified designee.
- Access to a consistent means of telephone contact
Exclusion Criteria:
- Presence of any febrile illness (oral temperature >38°C) on the day of immunization. Such subjects will be reevaluated for enrollment after resolution of illness.
- Presence of significant acute or chronic uncontrolled medical or neuropsychiatric illness and /or presence of any significant condition that may prohibit inclusion as determined by the investigator or his qualified designee. Uncontrolled is defined as: requiring institution of a new treatment within 1 month prior to study enrollment or change in medication dosage in the month prior to study enrollment.
- Any immunosuppressive condition including: history of HIV infection, cancer or cancer treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more days in total) within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study enrollment. Any significant disorder of coagulation that would increase the risk of intramuscular injections or treatment with Coumadin derivatives or heparin.
- Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza vaccine.
- History of severe or previous serious adverse reaction after an influenza vaccination.
- Receipt of any immunoglobulin and/or blood products within 3 months of immunization or planned administration of any of these products during the study period.
- Prior history of any demyelinating disease including Guillain-Barre syndrome.
- Presence of an active neurological disorder.
- History of significant alcohol or drug abuse within one year prior to study enrollment.
- Influenza vaccination or laboratory confirmed influenza infection within the previous six months before study vaccination or planned influenza vaccination during the study period.
- Planned administration of any non-influenza vaccines 30 days prior to the study or during the study period.
- Pregnant or plans to become pregnant during the study period.
- Currently enrolled in another vaccine or drug study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: STRATIS Needle-Free
Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
|
Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Inne nazwy:
|
|
Aktywny komparator: Needle-Syringe
Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
|
Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Ramy czasowe: 28 days
|
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.
|
28 days
|
|
Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Ramy czasowe: 28 days
|
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
|
28 days
|
|
Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Ramy czasowe: 28 days
|
The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.
|
28 days
|
|
Anti Influenza Type A/H1N1 Seroconversion
Ramy czasowe: 28 days
|
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
|
28 days
|
|
Anti Influenza Type A/H3N2 Seroconversion
Ramy czasowe: 28 days
|
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
|
28 days
|
|
Anti Influenza Type B Seroconversion
Ramy czasowe: 28 days
|
Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of ≥1:40.
|
28 days
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Subjects With Complaints Within 30 Minutes Following Vaccination
Ramy czasowe: Within 30 minutes post-vaccination
|
Within 30 minutes post-vaccination
|
|
|
Number of Subjects With Vaccine Reactogenicity Events
Ramy czasowe: Day 0, 1, 2, 3, 4, 5, and 6
|
Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination.
The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting.
Subjects will also record their oral temperature on the diary card each evening.
|
Day 0, 1, 2, 3, 4, 5, and 6
|
|
Number of Subjects With Spontaneously Reported Adverse Events
Ramy czasowe: 28 days
|
Subjects will be asked to report any other symptoms experienced in addition to the solicited "immediate" and "vaccine reactogenicity" events.
Any other events reported will be tabulated as spontaneously reported adverse events.
|
28 days
|
|
Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again
Ramy czasowe: 28 Days
|
28 Days
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: David K Cobb, MD, MPH, Rocky Mountain Infectious Disease Consultants
- Dyrektor Studium: Linda McAllister, MD, PhD, PharmaJet, Inc.
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- PJ-501-12-2
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .